Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.

Di Prospero NA, Baker A, Jeffries N, Fischbeck KH.

Lancet Neurol. 2007 Oct;6(10):878-86.

PMID:
17826341
2.

A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.

Lynch DR, Perlman SL, Meier T.

Arch Neurol. 2010 Aug;67(8):941-7. doi: 10.1001/archneurol.2010.168.

PMID:
20697044
3.

Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.

Di Prospero NA, Sumner CJ, Penzak SR, Ravina B, Fischbeck KH, Taylor JP.

Arch Neurol. 2007 Jun;64(6):803-8.

PMID:
17562928
4.

Friedreich's ataxia: idebenone treatment in early stage patients.

Artuch R, Aracil A, Mas A, Colomé C, Rissech M, Monrós E, Pineda M.

Neuropediatrics. 2002 Aug;33(4):190-3.

PMID:
12368988
5.

Pharmacological treatments for Friedreich ataxia.

Kearney M, Orrell RW, Fahey M, Brassington R, Pandolfo M.

Cochrane Database Syst Rev. 2016 Aug 30;(8):CD007791. doi: 10.1002/14651858.CD007791.pub4. Review.

PMID:
27572719
6.

Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.

Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR.

J Neurol. 2012 Feb;259(2):284-91. doi: 10.1007/s00415-011-6174-y. Epub 2011 Jul 22.

PMID:
21779958
7.

Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.

Ribaï P, Pousset F, Tanguy ML, Rivaud-Pechoux S, Le Ber I, Gasparini F, Charles P, Béraud AS, Schmitt M, Koenig M, Mallet A, Brice A, Dürr A.

Arch Neurol. 2007 Apr;64(4):558-64.

PMID:
17420319
8.

Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study.

Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rötig A.

Lancet. 1999 Aug 7;354(9177):477-9.

PMID:
10465173
9.

Antioxidants and other pharmacological treatments for Friedreich ataxia.

Kearney M, Orrell RW, Fahey M, Pandolfo M.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD007791. doi: 10.1002/14651858.CD007791.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;8:CD007791.

PMID:
22513953
10.

Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia.

Drinkard BE, Keyser RE, Paul SM, Arena R, Plehn JF, Yanovski JA, Di Prospero NA.

Arch Phys Med Rehabil. 2010 Jul;91(7):1044-50. doi: 10.1016/j.apmr.2010.04.007.

11.

Idebenone in Friedreich's ataxia.

Tonon C, Lodi R.

Expert Opin Pharmacother. 2008 Sep;9(13):2327-37. doi: 10.1517/14656566.9.13.2327 . Review.

PMID:
18710357
12.

Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia.

Hausse AO, Aggoun Y, Bonnet D, Sidi D, Munnich A, Rötig A, Rustin P.

Heart. 2002 Apr;87(4):346-9.

13.

Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia.

Rustin P, Rötig A, Munnich A, Sidi D.

Free Radic Res. 2002 Apr;36(4):467-9.

PMID:
12069112
14.

Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.

Velasco-Sánchez D, Aracil A, Montero R, Mas A, Jiménez L, O'Callaghan M, Tondo M, Capdevila A, Blanch J, Artuch R, Pineda M.

Cerebellum. 2011 Mar;10(1):1-8. doi: 10.1007/s12311-010-0212-7.

PMID:
20865357
15.

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

Pandolfo M, Arpa J, Delatycki MB, Le Quan Sang KH, Mariotti C, Munnich A, Sanz-Gallego I, Tai G, Tarnopolsky MA, Taroni F, Spino M, Tricta F.

Ann Neurol. 2014 Oct;76(4):509-21. doi: 10.1002/ana.24248. Epub 2014 Aug 30.

PMID:
25112865
16.

Antioxidants and other pharmacological treatments for Friedreich ataxia.

Kearney M, Orrell RW, Fahey M, Pandolfo M.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007791. doi: 10.1002/14651858.CD007791.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD007791.

PMID:
19821439
17.

Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.

Cooper JM, Schapira AH.

Biofactors. 2003;18(1-4):163-71. Review.

PMID:
14695932
18.

Oxidative stress in patients with Friedreich ataxia.

Schulz JB, Dehmer T, Schöls L, Mende H, Hardt C, Vorgerd M, Bürk K, Matson W, Dichgans J, Beal MF, Bogdanov MB.

Neurology. 2000 Dec 12;55(11):1719-21.

PMID:
11113228
19.

Neurophysiological evaluation in children with Friedreich's ataxia.

Sival DA, du Marchie Sarvaas GJ, Brouwer OF, Uges DR, Verschuuren-Bemelmans CC, Maurits NM, Brunt ER, van der Hoeven JH.

Early Hum Dev. 2009 Oct;85(10):647-51. doi: 10.1016/j.earlhumdev.2009.09.002. Epub 2009 Sep 22.

PMID:
19775837
20.

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.

Libri V, Yandim C, Athanasopoulos S, Loyse N, Natisvili T, Law PP, Chan PK, Mohammad T, Mauri M, Tam KT, Leiper J, Piper S, Ramesh A, Parkinson MH, Huson L, Giunti P, Festenstein R.

Lancet. 2014 Aug 9;384(9942):504-13. doi: 10.1016/S0140-6736(14)60382-2. Epub 2014 Apr 30.

Supplemental Content

Support Center